BioPharmX (BPMX) Earns Buy Rating from Analysts at Roth Capital

Roth Capital began coverage on shares of BioPharmX (NASDAQ:BPMX) in a research report sent to investors on Friday. The firm issued a buy rating and a $3.00 price objective on the stock.

Separately, HC Wainwright reissued a buy rating on shares of BioPharmX in a report on Saturday, September 17th.

BioPharmX (NASDAQ:BPMX) traded up 1.8059% during trading on Friday, reaching $0.4059. The company had a trading volume of 667,298 shares. The firm’s market capitalization is $27.49 million. BioPharmX has a one year low of $0.19 and a one year high of $1.84. The firm’s 50-day moving average price is $0.38 and its 200 day moving average price is $0.52.

BioPharmX (NASDAQ:BPMX) last released its quarterly earnings results on Tuesday, December 13th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. Equities analysts forecast that BioPharmX will post ($0.59) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/01/11/biopharmx-bpmx-earns-buy-rating-from-analysts-at-roth-capital.html.

In other news, Director Stephen Morlock purchased 428,571 shares of the stock in a transaction dated Monday, November 28th. The shares were purchased at an average cost of $0.35 per share, with a total value of $149,999.85. Following the acquisition, the director now directly owns 543,956 shares of the company’s stock, valued at $190,384.60. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

BioPharmX Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

5 Day Chart for NASDAQ:BPMX

What are top analysts saying about BioPharmX? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioPharmX and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit